Novel targets of antifibrotic and anti-inflammatory treatment in CKD

Area of Science:

• Nephrology
• Pathophysiology
• Translational Medicine

Background:

• Chronic kidney disease (CKD) is a global health crisis, exacerbated by rising rates of diabetes and obesity.
• Current treatments for CKD are limited, necessitating the development of novel therapeutic strategies.
• Understanding the underlying mechanisms of CKD is crucial for mitigating its impact and reducing the need for renal replacement therapy.

Purpose of the Study:

• To review recent advancements in understanding CKD pathogenesis.
• To highlight emerging therapeutic targets and approaches for CKD.
• To discuss the potential of disease-arresting therapies for CKD.

Main Methods:

• Review of current literature on CKD mechanisms and therapeutics.
• Focus on antifibrotic agents targeting the transforming growth factor β superfamily.
• Discussion of roles for vascular calcification, NADPH oxidase, inflammation, and kidney energy sensing pathways (AMPK, sirtuins, mTOR).
• Exploration of mitochondrial function and biogenesis in progressive kidney disease.

Main Results:

• New insights into CKD mechanisms involving fibrosis, vascular calcification, inflammation, and energy metabolism.
• Identification of potential therapeutic targets within the transforming growth factor β superfamily.
• Understanding the link between kidney energy sensing pathways, inflammation, and fibrosis.
• Emerging evidence on the role of mitochondrial health in CKD progression.

Conclusions:

• Novel therapeutic strategies for CKD are emerging from a deeper understanding of its complex pathogenesis.
• Antifibrotic agents and modulation of metabolic and inflammatory pathways show promise.
• Targeting mitochondrial function represents a new frontier in CKD treatment.
• These advancements offer renewed hope for improved clinical management of CKD.